We are conducting a study on feline patients to evaluate non-invasively collected specimens and, with the support of AI, identify biomarkers that may help distinguish IBD from EATL.
Currently Enrolling (Last Update: Aug 2025)
There is an outstanding need for a diagnostic that can discriminate between feline inflammatory bowel disease (IBD) and enteropathy-associated T-cell lymphoma (EATL), and there is evidence to show that non-disease related specimens have biological signatures that help with this effort.1-7 This study aims to identify key biomarkers from specimens that can be collected via non-invasive methods that, with the support of AI, can inform the diagnosis of IBD versus EATL.
To this end, the ImpriMed research team is seeking specimens from cats diagnosed by the current gold standard, histopathology, for one of these diseases. While our focus for lymphoma is on the EATL subtype, we can accept samples that are determined to be lymphoma but for which the subtype is unknown or inconclusive.
benefits to clinic
Your participation will contribute to the research and identification of new biomarkers to help distinguish IBD from EATL and will strongly support the development of non-invasive approaches for feline inflammation and cancer diagnostics.
We are requesting the samples from:
Feline patients with confirmed or suspected IBD versus EATL
For each patient, we request all of the following:
Patient samples
patient medical information
If you have not already, please register for access to our Vet Portal by clicking here. To submit sample information, go to ‘Sample Submission’ > Feline Services, and select 'Feline IBD vs EATL Pilot Study'
Please ensure all participating pet owners sign the consent form to allow us to use their cat’s sample for research. The results of this research study may be published or used for commercial purposes, but all identifying information for the pet or the client in any public documents will be deidentified to ensure confidentiality.
Interested in enrolling patients into this study? To get started, fill out the form or contact research@imprimedicine.com and we will send you the study protocol and detailed sample submission/shipping information.